Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve

References

• Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071. doi: 10.1097/HJH.0000000000003480
   PubMed Web of Science ®Google Scholar
• Unger T, Borghi C, Charchar F, et al. International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334–1357. doi: 10.1161/HYPERTENSIONAHA.120.15026
   PubMed Web of Science ®Google Scholar
• Caparrotta TM, Dear JW, Colhoun HM, et al. Pharmacoepidemiology: using randomised control trials and observational studies in clinical decision-making. Br J Clin Pharmacol. 2019;85(9):1907–1924. doi: 10.1111/bcp.14024
   PubMed Web of Science ®Google Scholar
• Anastasi JC, Norton M, McMahon DJ, et al. Recruitment and retention of clinical trial participants: understanding motivations of patients with chronic pain and other populations. Front Pain Res. 2024;44. doi: 10.3389/fpain.2023.1330937
   Google Scholar
• Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLOS Clin Trial. 2006;1(1):e9. doi: 10.1371/journal.pctr.0010009
   PubMedGoogle Scholar
• Lee EKP, Poon P, Yip BHK, et al. Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta‐analysis involving 27 million patients. J Am Heart Assoc. 2022;11(17):e026582. doi: 10.1161/JAHA.122.026582
   PubMed Web of Science ®Google Scholar
• Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–1117. doi: 10.1136/bmj.39553.670231.25
   PubMed Web of Science ®Google Scholar
• Cea-Calvo L, Marin-Jimenez I, de Toro J, et al. Different associations of intentional and non-intentional non-adherence behaviors with patient experience with healthcare and patient beliefs in medications: a survey of patients with chronic conditions. Patient Prefer Adherence. 2020;14:2439–2450. doi: 10.2147/PPA.S281985
   PubMed Web of Science ®Google Scholar
• Sabaté E. Adherence to long-term therapies: evidence for action. World Health Organization; 2003. p. 196.
   Google Scholar
• Foley L, Larkin J, Lombard-Vance R, et al. Prevalence and predictors of medication non-adherence among people living with multimorbidity: a systematic review and meta-analysis. BMJ Open. 2021;11(9):e044987. doi: 10.1136/bmjopen-2020-044987
   PubMed Web of Science ®Google Scholar
• Gossec L, Tubach F, Dougados M, et al. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. Am J Med Sci. 2007;334(4):248–254. doi: 10.1097/MAJ.0b013e318068dde8.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Julius S, Dahlof B, et al. Physician (investigator) inertia in apparent treatment-resistant hypertension – insights from large randomized clinical trials. Lennart Hansson memorial lecture. Blood Press. 2015;24(1):1–6. doi: 10.3109/08037051.2014.946787
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. doi: 10.1056/NEJMra050100
   PubMed Web of Science ®Google Scholar
• Mantila KM, Pasmooij AMG, Hallgreen CE, et al. Medication adherence measurement methods in registration trials supporting the approval of new medicines: a cross-sectional analysis of centralized procedures in the European Union 2010–2020. Clin Pharmacol Ther. 2022;112(5):1051–1060. doi: 10.1002/cpt.2709
   PubMed Web of Science ®Google Scholar
• Rudd P, Byyny RL, Zachary V, et al. Pill count measures of compliance in a drug trial: variability and suitability. Am J Hypertens. 1988;1(3 Pt 1):309–312. doi: 10.1093/ajh/1.3.309
   PubMed Web of Science ®Google Scholar
• Blaschke TF, Osterberg L, Vrijens B, et al. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2012;52(1):275–301. doi: 10.1146/annurev-pharmtox-011711-113247
   PubMed Web of Science ®Google Scholar
• Dodd S, White IR, Williamson P. Nonadherence to treatment protocol in published randomised controlled trials: a review. Trials. 2012;13(1):84. doi: 10.1186/1745-6215-13-84
   PubMedGoogle Scholar
• Vrijens B, Pironet A, Tousset E. The importance of assessing drug exposure and medication adherence in evaluating investigational medications: ensuring validity and reliability of clinical trial results. Pharmaceut Med. 2024;38(1):9–18. doi: 10.1007/s40290-023-00503-w
   PubMed Web of Science ®Google Scholar
• Baumgartner PC, Haynes RB, Hersberger KE, et al. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol. 2018;9:1290. doi: 10.3389/fphar.2018.01290
   PubMed Web of Science ®Google Scholar
• Reynolds NR, Sun J, Nagaraja HN, et al. Optimizing measurement of self-reported adherence with the ACTG adherence questionnaire: a cross-protocol analysis. J Acquir Immune Defic Syndr. 2007;46(4):402–409. doi: 10.1097/qai.0b013e318158a44f
   PubMed Web of Science ®Google Scholar
• Wilson IB, Lee Y, Michaud J, et al. Validation of a new three-item self-report measure for medication adherence. AIDS Behav. 2016;20(11):2700–2708. doi: 10.1007/s10461-016-1406-x
   PubMed Web of Science ®Google Scholar
• Lane D, Lawson A, Burns A, et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension. 2022;79(1):12–23. doi: 10.1161/HYPERTENSIONAHA.121.17596
   PubMed Web of Science ®Google Scholar
• Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855–861. doi: 10.1136/heartjnl-2013-305063
   PubMed Web of Science ®Google Scholar
• Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68(2):297–306. doi: 10.1161/HYPERTENSIONAHA.116.07464
   PubMed Web of Science ®Google Scholar
• Peeters LEJ, Kappers MHW, Hesselink DA, et al. Antihypertensive drug concentration measurement combined with personalized feedback in resistant hypertension: a randomized controlled trial. J Hypertens. 2024;42(1):169–178. doi: 10.1097/HJH.0000000000003585
   PubMed Web of Science ®Google Scholar
• Peeters LEJ, Feyz L, Boersma E, et al. Clinical applicability of monitoring antihypertensive drug levels in blood. Hypertension. 2020;76(1):80–86. doi: 10.1161/HYPERTENSIONAHA.120.15038
   PubMed Web of Science ®Google Scholar
• Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124–1140. doi: 10.1161/CIRCRESAHA.118.313220
   PubMed Web of Science ®Google Scholar
• Azizi M, Ezan E, Nicolet L, et al. High plasma level of N -acetyl-seryl-aspartyl-lysyl-proline. Hypertension. 1997;30(5):1015–1019. doi: 10.1161/01.hyp.30.5.1015
   PubMed Web of Science ®Google Scholar
• El Alili M, Vrijens B, Demonceau J, et al. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol. 2016;82(1):268–279. doi: 10.1111/bcp.12942
   PubMed Web of Science ®Google Scholar
• Vrijens B, Urquhart J. Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clin Pharmacol Ther. 2014;95(6):617–626. doi: 10.1038/clpt.2014.59
   PubMed Web of Science ®Google Scholar
• Burnier M, Schneider MP, Chiolero A, et al. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens. 2001;19(2):335–341. doi: 10.1097/00004872-200102000-00022
   PubMed Web of Science ®Google Scholar
• Checchi KD, Huybrechts KF, Avorn J, et al. Electronic medication packaging devices and medication adherence: a systematic review. JAMA. 2014;312(12):1237–1247. doi: 10.1001/jama.2014.10059
   PubMed Web of Science ®Google Scholar
• Eliasson L, Clifford S, Mulick A, et al. How the EMERGE guideline on medication adherence can improve the quality of clinical trials. Br J Clin Pharmacol. 2020;86(4):687–697. doi: 10.1111/bcp.14240
   PubMed Web of Science ®Google Scholar
• Frias J, Virdi N, Raja P, et al. Effectiveness of digital medicines to improve clinical outcomes in patients with uncontrolled hypertension and type 2 diabetes: prospective, open-label, cluster-randomized pilot clinical trial. J Med Internet Res. 2017;19(7):e246. doi: 10.2196/jmir.7833
   PubMed Web of Science ®Google Scholar
• Thompson D, Mackay T, Matthews M, et al. Direct adherence measurement using an ingestible sensor compared with self-reporting in high-risk cardiovascular disease patients who knew they were being measured: a prospective intervention. JMIR mHealth uHealth. 2017;5(6):e76. doi: 10.2196/mhealth.6998
   PubMed Web of Science ®Google Scholar
• Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;2015(5):CD003343. doi: 10.1002/14651858.CD003343.pub4
   PubMedGoogle Scholar
• Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389(3):228–238. doi: 10.1056/NEJMoa2208391
   PubMed Web of Science ®Google Scholar
• Subbiah V. The next generation of evidence-based medicine. Nat Med. 2023;29(1):49–58. doi: 10.1038/s41591-022-02160-z
   PubMed Web of Science ®Google Scholar
• Strom JB, Tamez H, Zhao Y, et al. Validating the use of registries and claims data to support randomized trials: rationale and design of the extending trial-based evaluations of medical therapies using novel sources of data (EXTEND) study. Am Heart J. 2019;212:64–71. doi: 10.1016/j.ahj.2019.02.007
   PubMed Web of Science ®Google Scholar
• Glassberg MB, Trygstad T, Wei D, et al. Accuracy of prescription claims data in identifying truly nonadherent patients. J Manag Care Spec Pharm. 2019;25(12):1349–1356. doi: 10.18553/jmcp.2019.25.12.1349
   PubMed Web of Science ®Google Scholar
• Bian S, Zhu B, Rong G, et al. Towards wearable and implantable continuous drug monitoring: a review. J Pharm Anal. 2021;11(1):1–14. doi: 10.1016/j.jpha.2020.08.001
   PubMed Web of Science ®Google Scholar
• Renard E. Implantable glucose sensors for diabetes monitoring. Minim Invasive Ther Allied Technol. 2004;13(2):78–86. doi: 10.1080/13645700410026993
   PubMed Web of Science ®Google Scholar
• Domingo-Lopez DA, Lattanzi G, L HJS, et al. Medical devices, smart drug delivery, wearables and technology for the treatment of diabetes mellitus. Adv Drug Deliv Rev. 2022;185:114280. doi: 10.1016/j.addr.2022.114280
   PubMed Web of Science ®Google Scholar
• Baryakova TH, Pogostin BH, Langer R, et al. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023;22(5):387–409. doi: 10.1038/s41573-023-00670-0
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–1401. doi: 10.1056/NEJMoa1402670
   PubMed Web of Science ®Google Scholar
• Azizi M, Pereira H, Hamdidouche I, et al. Adherence to antihypertensive treatment and the blood pressure–lowering effects of renal denervation in the renal denervation for hypertension (DENERHTN) trial. Circulation. 2016;134(12):847–857. doi: 10.1161/circulationaha.116.022922
   PubMed Web of Science ®Google Scholar
• de Jager RL, de Beus E, Beeftink MM, et al. Impact of medication adherence on the effect of renal denervation: The SYMPATHY trial. Hypertension. 2017;69(4):678–684. doi: 10.1161/hypertensionaha.116.08818
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Ott C, Schmid A, et al. Adherence to antihypertensive medication in treatment-resistant hypertension undergoing renal denervation. J Am Heart Assoc. 2016;5(2). doi: 10.1161/jaha.115.002343
   Web of Science ®Google Scholar
• Hosohata K. Impact of medication adherence on renal denervation trials in resistant hypertensive patients. Hypertens Res. 2023;46(10):2419–2420. doi: 10.1038/s41440-023-01381-0
   PubMed Web of Science ®Google Scholar
• Kario K, Kai H, Nanto S, et al. Anti-hypertensive medication adherence in the REQUIRE trial: post-hoc exploratory evaluation. Hypertens Res. 2023;46(8):2044–2047. doi: 10.1038/s41440-023-01333-8
   PubMed Web of Science ®Google Scholar
• Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927–1937. doi: 10.1016/S0140-6736(22)02034-7
   PubMed Web of Science ®Google Scholar
• Azizi M, Perdrix L, Bobrie G, et al. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin–angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. J Hypertens. 2014;32(10):2038–2044. doi: 10.1097/HJH.0000000000000280
   PubMed Web of Science ®Google Scholar
• Beaussier H, Boutouyrie P, Bobrie G, et al. True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence. J Hypertens. 2015;33(12):2526–2533. doi: 10.1097/HJH.0000000000000737
   PubMed Web of Science ®Google Scholar
• Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15. doi: 10.1136/bmj.38875.675486.55
   PubMed Web of Science ®Google Scholar
• Ogata A, Kaneko M, Narukawa M, et al. Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon. PLOS ONE. 2019;14(6):e0218534. doi: 10.1371/journal.pone.0218534
   PubMed Web of Science ®Google Scholar
• Shiovitz TM, Bain EE, McCann DJ, et al. Mitigating the effects of nonadherence in clinical trials. J Clin Pharmacol. 2016;56(9):1151–1164. doi: 10.1002/jcph.689
   PubMed Web of Science ®Google Scholar
• De Geest S, Zullig LL, Dunbar-Jacob J, et al. ESPACOMP medication adherence reporting guideline (EMERGE). Ann Intern Med. 2018;169(1):30–35. doi: 10.7326/m18-0543
   PubMed Web of Science ®Google Scholar